ENDRA Life Sciences Inc.
NDRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $5 | $7 | $5 |
| G&A Expenses | $7 | $0 | $0 | $0 |
| SG&A Expenses | $8 | $5 | $6 | $6 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $10 | $13 | $11 |
| Operating Income | -$11 | -$11 | -$13 | -$11 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | $0 | -$0 | $0 |
| Pre-Tax Income | -$12 | -$10 | -$13 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$10 | -$13 | -$11 |
| % Margin | – | – | – | – |
| EPS | -10.25 | -5.89 | -4.57 | -5.47 |
| % Growth | -74% | -28.9% | 16.5% | – |
| EPS Diluted | -10.25 | -5.89 | -6.84 | -5.47 |
| Weighted Avg Shares Out | 1 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 1 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$10 | -$13 | -$11 |
| % Margin | – | – | – | – |